The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
Open accessAbstract
Purpose: The adverse prognosis of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (ALL) prompted incorporation of monoclonal antibody therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone). Other modifications (irrespective of CD20 expression) included early anthracycline intensification, alterations in number of risk-adapted intrathecal chemotherapy treatments for CNS prophylaxis, additional early and late intensifications, and extension of maintenance phase chemotherapy by 6 months. Patients and Methods: Two hundred eighty-two adolescents and adults with de novo Philadelphia chromosome (Ph)–negative precursor B-lineage ALL were treated with standard or modified hyper-CVAD regimens. The latter incorporated standard-dose rituximab if CD20 expression ≥ 20%. Results: The complete remission (CR) rate was 95% with 3-year rates of CR duration (CRD) and survival (OS) of 60% and 50%, respectively. In the younger (age < 60 years) CD20-positive subset, rates of CRD and OS were superior with the modified hyper-CVAD and rituximab regimens compared with standard hyper-CVAD (70% v 38%; P < .001% and 75% v 47%, P = .003). In contrast, rates of CRD and OS for CD20-negative counterparts treated with modified versus standard hyper-CVAD regimens were similar (72% v 68%, P = not significant [NS] and 64% v 65%, P = NS, respectively). Older patients with CD20-positive ALL did not benefit from rituximab-based chemoimmunotherapy (rates of CRD 45% v 50%, P = NS and OS 28% v 32%, P = NS, respectively), related in part to deaths in CR. Conclusion: The incorporation of rituximab into the hyper-CVAD regimen appears to improve outcome for younger patients with CD20-positive Ph-negative precursor B-lineage ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Counting Processes and Survival Analysis.
Dabrowska, D. M., Fleming, T. R., & Harrington, D. P. (1992) · Journal of the American Statistical Association · doi:10.2307/2290673 · Cited by 2,271
Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues
Jaffe, E. S. (2003) · Cited by 2,141
Keating, M. J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.051 · Cited by 950
Self-citationResults of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.547 · Cited by 796
Self-citationTam, C. S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.-A., Thomas, D. A., Cortes, J., Lerner, S., & Keating, M. J. (2008) · Blood · doi:10.1182/blood-2008-02-140582 · Cited by 693
Self-citationKantarjian, H., Thomas, D., O'Brien, S., Cortes, J., Giles, F., Jeha, S., Bueso‐Ramos, C. E., Pierce, S., Shan, J., Koller, C., et al. (2004) · Cancer · doi:10.1002/cncr.20668 · Cited by 638
Self-citationThomas, D. A. (2004) · Blood · doi:10.1182/blood-2003-08-2958 · Cited by 571
Self-citationThomas, D. A., Faderl, S., O'Brien, S., Bueso‐Ramos, C., Cortes, J., Garcia‐Manero, G., Giles, F. J., Verstovsek, S., Wierda, W. G., Pierce, S. A., et al. (2006) · Cancer · doi:10.1002/cncr.21776 · Cited by 566
Self-citationRomaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.1825 · Cited by 557
Ravandi, F., O'Brien, S., Thomas, D., Faderl, S., Jones, D., Garris, R., Dara, S., Jorgensen, J., Kebriaei, P., Champlin, R., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261586 · Cited by 348
Self-citationLevels of expression of CD19 and CD20 in chronic B cell leukaemias.
Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., & Catovsky, D. (1998) · Journal of Clinical Pathology · doi:10.1136/jcp.51.5.364 · Cited by 325
Murphy, S. B., Bowman, W. P., Abromowitch, M., Mirro, J., Ochs, J., Rivera, G., Pui, C. H., Fairclough, D., & Berard, C. W. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.12.1732 · Cited by 267
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
Thomas, D. A., O'Brien, S., Cortes, J., Giles, F. J., Faderl, S., Verstovsek, S., Ferrajoli, A., Koller, C., Beran, M., Pierce, S., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4428 · Cited by 255
Self-citationFaderl, S., Thomas, D. A., O'Brien, S., Garcia-Manero, G., Kantarjian, H. M., Giles, F. J., Koller, C., Ferrajoli, A., Verstovsek, S., Pro, B., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1952 · Cited by 251
Self-citationCzuczman, M. S., Olejniczak, S., Gowda, A., Kotowski, A., Binder, A., Kaur, H., Knight, J., Starostik, P., Deans, J., & Hernandez-Ilizaliturri, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1254 · Cited by 232
Jabbour, E., O'Brien, S., Kantarjian, H., Garcia-Manero, G., Ferrajoli, A., Ravandi, F., Cabanillas, M., & Thomas, D. A. (2007) · Blood · doi:10.1182/blood-2006-08-043646 · Cited by 193
Self-citationJazirehi, A. R., Vega, M. I., & Bonavida, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2184 · Cited by 167
Leonard, J. P., Coleman, M., Ketas, J., Ashe, M., Fiore, J. M., Furman, R. R., Niesvizky, R., Shore, T., Chadburn, A., Horne, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.821 · Cited by 163
Weir, E., Cowan, K., Lebeau, P., & Borowitz, M. J. (1999) · Leukemia · doi:10.1038/sj.leu.2401364 · Cited by 145
Mechanism of action of rituximab.
Maloney, D. G. (2001) · PubMed · Cited by 106
Castillo, J. J., Milani, C., & Mendez-Allwood, D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902832679 · Cited by 68
Aberrant Underexpression of CD81 in Precursor B-Cell Acute Lymphoblastic Leukemia
Muzzafar, T., Medeiros, L. J., Wang, S. A., Brahmandam, A., Thomas, D. A., & Jorgensen, J. L. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcp02rpvoktnwec · Cited by 65
Self-citationPhiladelphia Chromosome–Positive Acute Lymphocytic Leukemia: A New Era of Challenges
Thomas, D. A. (2007) · Hematology · doi:10.1182/asheducation-2007.1.435 · Cited by 48
Self-citation
Cited by
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Self-citationAcute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Gu, Z., Churchman, M. L., Roberts, K. G., Moore, I., Zhou, X., Nakitandwe, J., Hagiwara, K., Pelletier, S., Gingras, S., Berns, H., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0315-5 · Cited by 603
Self-citation
Metadata
- Authors
- Thomas, D. A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J. L., Bueso-Ramos, C., Andreeff, M., Pierce, S., Garris, R., Keating, M. J., Cortes, J., & Kantarjian, H. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-08-20
- Volume
- 28
- Issue
- 24
- Pages
- 3880-3889
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123755151
- Cited by
- 416
- References
- 31
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.